据财联社主题库显示，相关上市公司中：According to the latest data from the China Center for Disease Control and Prevention, the positive rate of influenza viruses has been continuously rising, with over 99% being type A influenza. With the increase in the number of influenza infections, the sales of Anti-Influenza drugs have also been continuously growing recently. Currently, the available antiviral drugs for influenza in the country mainly include Oseltamivir, Abidor, Marbofloxacin, Zanamivir, and Peramivir.
According to the latest data from the China Center for Disease Control and Prevention, the positive rate of influenza viruses has been continuously rising, with over 99% being type A influenza. Health authorities in many parts of the country have issued urgent reminders to enhance personal protection and take precautions against respiratory and intestinal infectious diseases.
With the increase in influenza infections, the sales of Anti-Influenza drugs have also been continuously growing recently. Currently, the available antiviral drugs for influenza in the country mainly include Oseltamivir, Abidor, Marbofloxacin, Zanamivir, and Peramivir. However, compared to Other drugs, Marbofloxacin has become more popular recently. Winter is the peak period for influenza outbreaks. Following Oseltamivir, Marbofloxacin, which requires only one dose for the entire course of treatment, has become the new generation of 'miraculous drug for influenza', triggering another wave of medication purchasing frenzy. Investigations by the Blue Whale reporter found that many pharmacies are facing tight stocks of Marbofloxacin, with some pharmacies already sold out.
According to data from the financial news agency, among the relevant listed companies:
Guangdong Zhongsheng Pharmaceutical announced on the evening of November 17, 2024, that its subsidiary, Zhongsheng Ruichuang, has completed the enrollment of the first case in the clinical phase II trial of Anglawei granules. This drug exhibits significantly superior inhibition capabilities against various type A influenza viruses compared to Oseltamivir and Marbofloxacin, showing market potential.
Brightgene Bio-Medical Technology Co.,Ltd. has obtained production approval documents for Oseltamivir phosphate capsules and Oseltamivir phosphate dry suspension. The company's Oseltamivir phosphate dry suspension won the bid in the eighth national centralized drug procurement, with a winning price of 15.99 yuan per box.
